Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.
Article
PubMed
Google Scholar
Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, et al: Breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2006, 4: 480-508.
PubMed
Google Scholar
Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually. J Natl Cancer Inst. 1989, 81: 1879-1886. 10.1093/jnci/81.24.1879.
Article
CAS
PubMed
Google Scholar
National Comprehensive Cancer Network: Practice Guidelines in Oncology – Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2005, National Comprehensive Cancer Network, Inc, 1.
Google Scholar
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002, 359: 909-919. 10.1016/S0140-6736(02)08020-0.
Article
PubMed
Google Scholar
Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA: Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001, 91: 1724-1731. 10.1002/1097-0142(20010501)91:9<1724::AID-CNCR1190>3.0.CO;2-V.
Article
CAS
PubMed
Google Scholar
Le-Petross HT: Breast MRI as a screening tool: the appropriate role. J Natl Compr Canc Netw. 2006, 4: 523-526.
PubMed
Google Scholar
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.
Article
CAS
PubMed
Google Scholar
Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA: Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005, 103: 1898-1905. 10.1002/cncr.20971.
Article
PubMed
Google Scholar
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. Jama. 2004, 292: 1317-1325. 10.1001/jama.292.11.1317.
Article
CAS
PubMed
Google Scholar
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004, 351: 427-437. 10.1056/NEJMoa031759.
Article
CAS
PubMed
Google Scholar
Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005, 23: 8469-8476. 10.1200/JCO.2004.00.4960.
Article
PubMed
Google Scholar
Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM: Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006, 295: 2374-2384. 10.1001/jama.295.20.2374.
Article
CAS
PubMed
Google Scholar
Tumeh JW, Moore SG, Shapiro R, Flowers CR: Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2005, 5: 153-162. 10.1586/14737167.5.2.153.
Article
Google Scholar
Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO: Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer. 2006, 95: 801-810. 10.1038/sj.bjc.6603356.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wainberg S, Husted J: Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1989-1995.
CAS
PubMed
Google Scholar
Arias E: United States life tables, 2002. National vital statistics reports. 2004, Hyattsville, Maryland: National Center for Health Statistics, 53.
Google Scholar
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.
Article
Google Scholar
van Roosmalen MS, Verhoef LCG, Stalmeier PFM, Hoogerbrugge N, van Daal WAJ: Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy. J Clin Oncol. 2002, 20: 2092-2100. 10.1200/JCO.2002.08.035.
Article
PubMed
Google Scholar
Messecar DC: Mammography screening for older women with and without cognitive impairment. J Gerontol Nurs. 2000, 26: 14-24.
Article
CAS
PubMed
Google Scholar
de Haes JCJM, de Koning HJ, van Oortmarssen GJ, van Agt HME, de Bruyn AE, van der Maas PJ: The impact of a breast cancer screening programme on quality-adjusted life-years. International Journal of Cancer. 1991, 49: 538-544. 10.1002/ijc.2910490411.
Article
CAS
PubMed
Google Scholar
Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C: Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004, 91: 1893-1901. 10.1038/sj.bjc.6602230.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levin HM, McEwan PJ: Cost-Effectiveness Analysis: Methods and Applications. 2000, Sage Publications, Inc, 2
Google Scholar
Bonneterre J, Bercez C, Bonneterre ME, Lenne X, Dervaux B: Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol. 2005, 16: 915-922. 10.1093/annonc/mdi195.
Article
CAS
PubMed
Google Scholar
Brouwer W, van Hout B, Rutten F: A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy. 2000, 5: 114-118.
CAS
PubMed
Google Scholar
van Asperen CJ, Tollenaar RAEM, Krol-Warmerdam EMM, Blom J, Hoogendoorn WE, Seynaeve CMJC, Brekelmans CTM, Devilee P, Cornelisse CJ, Klijn JGM, de Bock GH: Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet. 2003, 11: 633-636. 10.1038/sj.ejhg.5201021.
Article
CAS
PubMed
Google Scholar